Valneva (VALN) to Release Quarterly Earnings on Thursday

Valneva (NASDAQ:VALN) will likely be releasing its Q3 2025 results before the market opens on Thursday, November 20th. Analysts expect Valneva to post earnings of ($0.30) per share and revenue of $48.8520 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 20, 2025 at 7:00 AM ET.

Valneva Stock Performance

Shares of VALN stock opened at $8.79 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77. The company’s fifty day moving average price is $9.82 and its two-hundred day moving average price is $8.15. The firm has a market capitalization of $755.76 million, a P/E ratio of -8.97 and a beta of 1.83. Valneva has a 12 month low of $3.62 and a 12 month high of $12.25.

Analyst Ratings Changes

Several research firms recently commented on VALN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Valneva in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Valneva in a research report on Monday, August 25th. Wall Street Zen raised shares of Valneva to a “hold” rating in a research report on Saturday, September 6th. Jefferies Financial Group set a $14.00 price target on shares of Valneva and gave the stock a “buy” rating in a research note on Monday, August 25th. Finally, Guggenheim cut their price target on shares of Valneva from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Monday, September 8th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Valneva has an average rating of “Moderate Buy” and an average price target of $15.00.

Institutional Investors Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. Marex Group plc acquired a new position in Valneva SE Sponsored ADR (NASDAQ:VALN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 11,300 shares of the company’s stock, valued at approximately $64,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.